This article was originally published on this site
Advaxis Inc. (ADXS) had a rough trading day for Wednesday July 11 as shares tumbled 7.64%, or a loss of $-0.11 per share, to close at $1.33. After opening the day at $1.40, shares of Advaxis Inc. traded as high as $1.42 and as low as $1.33. Volume was 998,223 shares over 2,150 trades, against an average daily volume of 761,818 shares and a total float of 52.62 million.
As a result of the decline, Advaxis Inc. now has a market cap of $69.99 million. In the last year, shares of Advaxis Inc. have traded between a range of $7.45 and $1.40, and its 50-day SMA is currently $1.71 and 200-day SMA is $2.57.
For a complete fundamental analysis of Advaxis Inc., check out Equities.com’s Stock Valuation Analysis report for ADXS.
Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading
Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.
Advaxis Inc. is based out of Princeton, NJ and has some 108 employees. Its CEO is Kenneth A. Berlin.
Advaxis Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
To get more information on Advaxis Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ADXS’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer